Novartis AG

Otsuka’s release of supplemental Phase III data on June 6 for sibeprenlimab was the second major data readout in immunoglobulin A nephropathy (IgAN) of the week, following Vera’s Phase III data on Jun

The Maryland Prescription Drug Affordability Board (PDAB) does not automatically assume an upper payment limit is the go-to solution for drug affordability concerns, Executive Director Andrew York sai

For the third time, the Federal Trade Commission has sent out warning letters to drug companies, disputing improperly listed patents in the US Food and Drug Administration’s Orange Book. In this round

The pharmaceutical industry in Europe has criticized the Council of the EU’s adoption of a package of legislative reforms for medicines, claiming that the continent’s innovation-unfriendly environment